Answers are grounded in this paper and cite their sources.
Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disease characterized by progressive skeletal muscle denervation due to deterioration of the alpha-motoneurons and consequently by the occurrence of hypotonia, muscle weakness, atrophy. The aim of our research is to demonstrate the potential impact of SMN2 gene copies on the development of one of the three types of SMA patients in the period from 2001 to 2013 year. The study included 74 patients (44 females and 30 males) fulfilling clinical diagnostic criteria for SMA. The patients were classified in a particular category of SMA (type 1, 2 or 3). Ability to sit/walk unaided was taken as the main criterion in the patient classification. 8 patients were classified as type 1 (11.3%), 27 as type 2 (38%), while 36 (50.7%) as type 3 of SMA. Homozygous gene deletions SMN1 was represented in 72/74 (97.2%) of the patients. Remaining two patients are compound heterozygotes with an absence of one SMN1 allele and a small mutation in the other. The number of SMN2 gene copies was significantly lower in SMA type 1 patients than in SMA type 2 and type 3 patients, which showed a highly statistically significant difference (p < 0.001). In this study we found that the number of copies of SMN2 gene correlated with the phenotype of SMA patients by decreasing the severity, which can be used as one of the indispensable prognostic parameters of disease.
No takes yet. Share an insight, caveat, or question.
Knežević et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: